Market is being manipulated higher as big money is pulling out ahead of a looming huge crash. That is what I see. (8/2/12)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How are ya boss?
Be careful with their A/S increase Bull. 7.5B now.
GM Lot.
Wow, nice. Thanks for the short update. I like this one alot bird. Thanks again.
College, maybe this will help you with EFIR as far as S/S...You had asked about that and with the numbers on pinks being outdated I am trying to help out some if I can:
Per you question about S/S:
#
Outstanding Shares
1,184,257,619 as of Jun 30, 2008
#
Authorized Shares
1,320,000,000 as of Jun 30, 2008
However, notice this also:
shs decreased by 1 for 200 split
Pay Date: Oct 8, 2008
If you factor that split in Oct 08, the update would be:
O/S: 5,921,288
Obviously that number is higher since then, but not back to a billion by any stretch of the imagination.
Dec 2008 O/S was 6,921,288
As of September 30, 2009, the registrant had 28,654,467 shares of its $0.001 par value common stock issued and outstanding. There are also -0- shares of Series A, or B preferred stock, and 5,000 shares of its Series C preferred stock, issued and outstanding, at $0.001 par value for each of the Series of Preferred, and no shares of non-voting common stock issued and outstanding.
From what I find, that is the last and most updated number. If you figure that in 9 months they changed O/S from 6.9M to 28.6M then at this point at that rate of increase, (6 1/2 months @ 2.4M/month) = increase of 15.66M or O/S of 44.3M.
Hope that helps some.
Per you question about S/S:
#
Outstanding Shares
1,184,257,619 as of Jun 30, 2008
#
Authorized Shares
1,320,000,000 as of Jun 30, 2008
However, notice this also:
shs decreased by 1 for 200 split
Pay Date: Oct 8, 2008
If you factor that split in Oct 08, the update would be:
O/S: 5,921,288
Obviously that number is higher since then, but not back to a billion by any stretch of the imagination.
Dec 2008 O/S was 6,921,288
As of September 30, 2009, the registrant had 28,654,467 shares of its $0.001 par value common stock issued and outstanding. There are also -0- shares of Series A, or B preferred stock, and 5,000 shares of its Series C preferred stock, issued and outstanding, at $0.001 par value for each of the Series of Preferred, and no shares of non-voting common stock issued and outstanding.
From what I find, that is the last and most updated number. If you figure that in 9 months they changed O/S from 6.9M to 28.6M then at this point at that rate of increase, (6 1/2 months @ 2.4M/month) = increase of 15.66M or O/S of 44.3M.
Hope that helps some.
EFIR I like a lot college. Check that one out. You might like this post I found on Yahoo msg about it.
Interesting post from Yahoo msg board:
To answer that question watch the Company's press releases very closely. hillbilly will signal the target price by making noise in the press about the # of shares outstanding (and limits thereto), the anticipated revenue of the acquisitions, and raising money to actually close the acquisitions.
The last release about Kodiak was the share release, message being "for now there will only be about ~29M shares outstanding."
he has already told you he expects revenues of 26M after the Southwest Signal acquisition in the 3/19 release.
Now the trigger will be the release that he actually closed the financing to fund and close the acquisition.
The way this game is played is that generally the fast money speculativss will go ahead and give the company a 1X revenue valuation ahead of examining the fundamentals/particulars and bid the price up accordingly.
So do the math: 1X 26M / 29M shares = ~0.90/share. With a little irrational exuburance from the market you get to $1/share. I bet that's the target give or take.
Understand of course that it's all a shell game and will come unwound once the market realizes the fundamentals don't support the initial read on the stock.
Oh ya, one last thing, the 20X+ increase in volume the week of 3/29 was all hillbilly's insider buddies loading up on virtually free stock before the runup....
Wow, 17k% in 6 months? That is nearly unbelievable.
EFIR had a nice day today and seems to be coming off bottom. I grabbed me some of those and am looking for a strong week from them next week.
PPJE increased their authorized shares to 7.5B.
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=mfueUqwrlF3DPmD5ebT8Gw%253d%253d&nt7=0
The trading window for this one has gotten so tight. Building a new base for a stronger and higher move.
Interesting post from Yahoo msg board:
To answer that question watch the Company's press releases very closely. hillbilly will signal the target price by making noise in the press about the # of shares outstanding (and limits thereto), the anticipated revenue of the acquisitions, and raising money to actually close the acquisitions.
The last release about Kodiak was the share release, message being "for now there will only be about ~29M shares outstanding."
he has already told you he expects revenues of 26M after the Southwest Signal acquisition in the 3/19 release.
Now the trigger will be the release that he actually closed the financing to fund and close the acquisition.
The way this game is played is that generally the fast money speculativss will go ahead and give the company a 1X revenue valuation ahead of examining the fundamentals/particulars and bid the price up accordingly.
So do the math: 1X 26M / 29M shares = ~0.90/share. With a little irrational exuburance from the market you get to $1/share. I bet that's the target give or take.
Understand of course that it's all a shell game and will come unwound once the market realizes the fundamentals don't support the initial read on the stock.
Oh ya, one last thing, the 20X+ increase in volume the week of 3/29 was all hillbilly's insider buddies loading up on virtually free stock before the runup....
Wow, College u were very early on SNPY. Nice find and alert. Person mark for ya.
BNFR listed here first last night. Was .01. R/M in the works. Up 2000% today.
I'll take EFIR.
Looking deep into this one. Like what I see so far. Plan to add some on Monday. Hate that I missed under .01 today :(. Oh well. Still seems like a steal here.
Really nice closing volume here today.
EFIR had a strong close today. Thanks for the heads up.
Thx. Have to check that one out.
LOL.....hadn't thought of that. :)
Not sure that smell is money with this group. LOL
8-k filing on that boss:
Item 7.01 Regulation FD Disclosure.
On April 9, 2010, Cell Therapeutics, Inc.’s (the “Company”) following a mandatory request from CONSOB pursuant to Section 114 of Legislative Decree n. 58/1998, issued an Italian press release in Italy entitled “Cell Therapeutics Provides Information Regarding Reports of Possible Takeover Bids by Novartis.” In the press release, the Company confirmed what was previously disclosed on its March 25, 2010 conference call that the Company is in discussions with Novartis Oncology with regards to development and commercialization of its pixantrone drug candidate, but has no comment on the reports of a potential takeover of the Company by Novartis. An English translation of the press release is furnished and not filed pursuant to Item 7.01 as Exhibit 99.1 hereto.
CTIC news:
CTI Receives Complete Response Letter from the FDA for Pixantrone NDA; CTI to File for Expanded Access for Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Friday 04/09/2010 1:15 AM ET - Pr Newswire
Related Companies
Symbol Last %Chg
CTIC 0.64 0.00%
As of 4:00 PM ET 4/8/10
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration (the "FDA") regarding its New Drug Application ("NDA") for Pixuvri(TM) (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). The FDA cited as its primary reason for the action its concerns previously raised at the Oncologic Drugs Advisory Committee ("ODAC") meeting on March 22, 2010 and recommended the Company conduct an additional trial to demonstrate the safety and effectiveness of its product. Based on the FDA's ODAC presentation, which provided the Committee and the Company with alternative options to consider to make investigational drugs available to patients if drugs need to be studied further prior to approval, the Company has decided to pursue expanded access program for pixantrone while it conducts an additional study in aggressive NHL.
"On the basis of discussing the PIX 301 clinical trial results with directors of more than 50 of the largest academic and community based lymphoma treatment centers across the U.S., we expect enrollment in a follow-up combination therapy study in a similar population could be rapid and occur predominantly within the U.S.," noted Jack W. Singer, M.D., Chief Medical Officer of the Company. "We have had preliminary discussions on the subsequent trial design with a leading statistician, and potential lead investigators who believe the study will be positively received by the lymphoma treatment community on the basis of the PIX 301 clinical trial results and the lack of satisfactory alternative therapies for their patients with multiple relapsed aggressive non-Hodgkin's lymphoma."
"This is a sad outcome for our patients with relapsed/refractory aggressive NHL," said Dr. Stanley M. Marks, Director of Clinical Services and Chief Medical Officer for the University of Pittsburgh Cancer Centers ("UPMC") and Chief of the Division of Hematology/Oncology at UPMC. "I was disappointed that an agency charged with providing treatment hope for patients with life threatening diseases like relapsed/refractory NHL would ignore clinically meaningful improvements in overall response rate and progression-free survival, let alone complete responses, something we all wish for our patients, but with existing treatments rarely achieve."
The Company plans to request a meeting with the FDA on both the design of the follow-on study as well as expanded access program for patients who are not participating in the Company's clinical trial.
Later this month, the Company is scheduled to meet with its clinical expert and the co-rapporteurs as it prepares to submit its Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMEA") for review. Based on their feedback and guidance, the Company expects to submit the application in the third quarter of 2010.
About Pixantrone
Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines --rather than intercalation with DNA--, pixantrone alkylates DNA --forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production,--- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.
About Non-Hodgkin's Lymphoma
NHL is caused by the abnormal proliferation of lymphocytes, cells key to the functioning of the immune system. It usually originates in lymph nodes and spreads through the lymphatic system. NHL can be broadly classified into two main forms--aggressive NHL is a rapidly growing form of the disease that moves into advanced stages much faster than indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database, on January 1, 2006 there were approximately 419,533 people in the U.S. living with a history of NHL. The American Cancer Society estimated that 65,980 people would be diagnosed with NHL in 2009 with 19,500 estimated to die from this disease. It is the fifth most common cancer in the United States.
There are many subtypes of NHL, but aggressive NHL is one of the more common types of NHL and accounts for about 60% of cases. Initial therapy for aggressive NHL with anthracycline-based combination therapy cures up to 50 percent of patients. Of the remaining patients, approximately half will respond to second-line treatment, but few are cured and there is no effective therapy for patients relapsing after or refractory to second-line treatment.
About Cell Therapeutics, Inc.
Headquartered in Seattle, the Company is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.
Sign up for email alerts and get RSS feeds at the Company's Web site, http://www.CellTherapeutics.com/investors_alert
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the Company's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA, that the FDA may not accept the Company's proposed design for the protocol of the Company's clinical trial and/or may request additional clinical trials, that if the Company conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of pixantrone, that the Company cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that the Company may not be able to pursue an expanded access program for pixantrone, that the FDA may not grant the Company a meeting to discuss the design of the follow-on study or expanded access program, that the Company may not submits its MAA to the EMEA in the third quarter of 2010, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, the Company does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
BNFR involved in a reverse merger. Check the 8-k from this evening. 30M float. Worth a watch.
PDGE wasn't bad today. Dipped after a big am gap and then closed strong.
ASFG on watch. Being gobbled up by insiders for some reason.
People gonna wake up soon to this one.
PDGE just a typical dip here. More to come.
PDGE hasn't even woken up yet man.
PDGE building nicely college. Me likey.
PDGE razor thin fozy.
PDGE lookin really nice here Pink.
PDGE lookin really nice here Pink.
PDGE ready to rumble for real here soon.
PDGE ready to rumble for real here soon.
PDGE lookin good Wowser
PDGE up 66% and rising. Gonna blow
PDGE up 58% and rising. Gonna blow
Hey cargo...PDGE gapping already. About to blow big time.